# The Ensign Group, Inc. Increases Quarterly Dividend to $0.0650 Per Share
Canonical URL: https://biopharmsignal.com/news/ENSG/the-ensign-group-inc-increases-quarterly-dividend-to-0-0650-per-share-c3debdc1
Ticker: ENSG
Company: Ensign Group
Source: Ensign Group
Published: 2025-12-19 11:00 EST
## Summary

The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of...

## Article Body
The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.0650 per share of Ensign common stock, payable on or before January 31, 2026, to shareholders of record as of December 31, 2025. “We are proud to announce our twenty-third consecutive annual dividend increase, which is a reflection on our strong market position and commitment to return value to our shareholders,” commented Barry Port, Ensign's Chief Executive Officer. “We are excited for the upcoming year and what it will bring for our organization and shareholders,” he added.

Ensign has been a dividend-paying company since 2002.

About Ensign ™

The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 373 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net .

Contact Information

The Ensign Group, Inc., (949) 487-9500, ir@ensignservices.net

SOURCE: The Ensign Group, Inc.
## Recent Company News
- 2026-07-27 10:04 EST — [The Ensign Group Reports Second Quarter 2026 Results](https://biopharmsignal.com/news/ENSG/the-ensign-group-reports-second-quarter-2026-results-74822708) — Source: Ensign Group
- 2026-07-02 10:00 EST — [The Ensign Group Purchases Real Estate and Operations in Texas](https://biopharmsignal.com/news/ENSG/the-ensign-group-purchases-real-estate-and-operations-in-texas-fafd93f0) — Source: Ensign Group
- 2026-06-19 10:00 EST — [The Ensign Group, Inc. Declares Quarterly Dividend of $0.0650 Per Share](https://biopharmsignal.com/news/ENSG/the-ensign-group-inc-declares-quarterly-dividend-of-0-0650-per-share-0f946fe9) — Source: Ensign Group
- 2026-06-15 20:05 EST — [The Ensign Group, Inc. Announces Increased Stock Repurchase Authorization](https://biopharmsignal.com/news/ENSG/the-ensign-group-inc-announces-increased-stock-repurchase-authorization-63cb7613) — Source: Ensign Group
- 2026-06-02 10:00 EST — [The Ensign Group Purchases Memory Care Facility in California](https://biopharmsignal.com/news/ENSG/the-ensign-group-purchases-memory-care-facility-in-california-644602e8) — Source: Ensign Group
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)